NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Copy of Newspaper Publication of Postal Ballot Notice26-02-2024
26-02-2024
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor meet on February 28, 202423-02-2024
NATCO PHARMA LTD. - 524816 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Notice of Postal Ballot dated February 14, 202422-02-2024
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Concall Transcript for the quarter and nine months ended December 31, 202321-02-2024
Pharma stocks make strong moves on robust results, positive outlook; Natco zooms 14%
Shares of Natco, Glenmark and Aurobindo Pharma are up 14, 10 and 2 percent respectively in the session.16-02-2024
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio recording of earnings conference call Q3 FY2415-02-2024
Natco Pharma Results Earnings Call for Q3FY24
Conference Call with Natco Pharma Management and Analysts on Q3FY24 Performance and Outlook. Listen to the full earnings transcript.15-02-2024
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Copy of Newspaper Publication for the quarter and nine months ended 31st December 202315-02-2024
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation for the quarter and nine months ended December 31, 202315-02-2024
Natco Pharma Q2 Net Profit Surges Over 6-Fold To Rs 369 Crore
Consolidated total revenue rose to Rs 1,061 crore for the period under review, as compared with Rs 453 crore in the year-ago period, Natco Pharma said in a regulatory filing.14-02-2024